Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small Molecule for Huntington's Disease
- Written by PR Newswire
SKY-0515 is a small molecule RNA splicing modifier developed through the company's novel SKYSTAR® platform. SKY-0515's Phase 1 study will include healthy volunteers before targeting Huntington's patients. Huntington's disease is a fatal neurological disease with no curative therapies.
WALTHAM, Mass., Oct. 23, 2023 /PRNewswire/ --...
